Cannabis

10 Aug Frequent cannabis users show higher cortisol levels at awakening compared to controls

Posted at 20:37h in addiction-treatment, Author Interviews, Cannabis, Sleep Disorders

Cannabis and CBD Product Notice: Cannabis and CBD products are not FDA-monitored or approved for the treatment of anxiety, depression, or any other mental health condition and are not legal in all locations. Effects vary significantly between individuals. Do not use if you are pregnant, nursing, or may become pregnant. Keep out of reach of children. Children and pets should not be exposed to these products. Cannabis and CBD products may interact with alcohol and other drugs including prescription medications. Always consult your physician or qualified healthcare provider before using any cannabinoid product, especially if you have an existing health condition or take other medications.

MedicalResearch.com Interview with:

Anita Cservenka, PhD

Associate Professor; Director, Substance Use & Neurocognition Lab

School of Psychological Science, Oregon State University, Corvallis, OR

[caption id="attachment_75520" align="alignleft" width="200"]

Dr. Cservenka, PhD[/caption]

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Cservenka: There had been limited research on whether frequent cannabis use is associated with changes in individuals' diurnal stress activity, which can be measured by examining the cortisol awakening response. However, some previous studies had shown that the typical rise of cortisol in the morning, which is thought to be a marker of our body's preparation for managing the stressors of the day, may be blunted among individuals with alcohol use disorder. A recent study by Glodosky et al., 2026, also suggested this may be the case among those with chronic cannabis use, so we attempted to replicate those findings. Although we did not find group differences in the cortisol awakening response (the difference in cortisol 30 minutes post-awakening and at the time of awakening) between individuals who engaged in frequent cannabis use relative to controls, we did find that cannabis use may be related to higher levels of cortisol at the time of awakening and this was significantly related to cannabis use consequences.

Watch the Video of this interview

06 Aug The Evolving Role of Clinical Oversight in Medical Cannabis Therapy

Posted at 11:41h in Addiction, Cannabis

Cannabis and CBD Product Notice: Cannabis and CBD products are not approved for the treatment of anxiety, depression, or any other mental health condition. Effects vary significantly between individuals. Do not use if you are pregnant, nursing, or may become pregnant. Keep out of reach of children. Children and pets should not be exposed to these products. Cannabis and CBD products may interact with alcohol and other drugs including prescription medications. Always consult your physician or qualified healthcare provider before using any cannabinoid product, especially if you have an existing health condition or take other medications. In Australia, medicinal cannabis products are regulated by the Therapeutic Goods Administration and must be accessed through authorised prescribers or approved access pathways.

Up to January 2024, the number of Australian patients utilising unregistered medicinal cannabis products skyrocketed to over one million, marking a dramatic increase from roughly 18,000 in 2019. In 2024 alone, the Therapeutic Goods Administration authorised nearly a million prescription applications through specialised access pathways. However, this massive surge in accessibility has prompted a necessary shift in focus. The medical community is increasingly moving away from merely providing access to alternative therapies, pivoting instead toward strict clinical oversight to ensure patient safety and long-term efficacy.

Due to the complexities of integrating cannabinoid therapies with existing medications, patients are now shifting away from direct supply clinics. Instead, many are consulting with a natural medicine dispensary to access tailored, heavily regulated plant-based treatments under the supervision of trained pharmacists and naturopaths. This clinical environment ensures that treatments are rooted in scientific evidence rather than retail convenience.

[caption id="attachment_75471" align="aligncenter" width="500"]

Photo by Terrance Barksdale[/caption]

Cannabis and CBD Product Notice: Cannabis and CBD products are not FDA-monitored or approved for the treatment of anxiety, depression, or any other mental health condition and are not legal in all locations. Effects vary significantly between individuals. Do not use if you are pregnant, nursing, or may become pregnant. Keep out of reach of children. Children and pets should not be exposed to these products. Cannabis and CBD products may interact with alcohol and other drugs including prescription medications. Always consult your physician or qualified healthcare provider before using any cannabinoid product, especially if you have an existing health condition or take other medications. MedicalResearch.com Interview with: Ryan M. Sullivan, PhD Postdoctoral Research Fellow, UC San Diego School of Medicine [IMAGE GOES HERE] Study: Sullivan RM, Wallace AL, Shankula CA, et al. Substance use patterns from late childhood to mid-adolescence: Updates on the Adolescent Brain Cognitive Development Study. Drug and Alcohol Dependence Reports. 2026;20:100463. https://doi.org/10.1016/j.dadr.2026.100463 MedicalResearch.com: What is the background for this study? Dr. Sullivan: Adolescence is a critical period for brain development and a time when many young people begin experimenting with alcohol, cannabis, nicotine and other substances. Understanding when substance use begins, how it changes as young people get older, and which substances are most commonly used together can help researchers identify opportunities for prevention and better understand how early substance use may relate to later health outcomes. This study used data from the Adolescent Brain Cognitive Development (ABCD) Study, one of the largest longitudinal studies of youth in the United States, to provide an updated picture of substance use patterns from late childhood through mid-adolescence. Related MedicalResearch.com research has also found that cognitive brain circuits are altered in youth with significant cannabis use — underlining why tracking when and how adolescents begin using substances matters for understanding long-term neurodevelopmental outcomes. MedicalResearch.com: What are the main findings? Dr. Sullivan: The study found that substance use increased steadily as participants moved through adolescence. By age 16, 38% of participants reported having used at least one substance during their lifetime. Alcohol, cannabis and nicotine were the substances most commonly reported. The researchers also identified differences by sex. Boys reported higher rates of substance use before age 12, but beginning around age 13, girls reported higher rates of alcohol, cannabis and nicotine use, with the largest differences seen for nicotine. Polysubstance use — using two or more substances — was also relatively common, with nearly 15% of participants reporting it during the study. The most common combination was nicotine and cannabis, and girls reported higher rates of polysubstance use after age 13, particularly combinations involving nicotine. Importantly, estimates adjusted to better reflect the U.S. population were very similar to the study's unadjusted estimates, suggesting that the ABCD cohort provides a useful representation of national patterns of adolescent substance use. MedicalResearch.com: What should readers take away from your report? Dr. Sullivan: The key takeaway is that substance use becomes increasingly common as young people move through adolescence, highlighting the importance of prevention and early intervention before or during the early teen years. The findings also show that substance use does not follow the same pattern for everyone. In particular, the shift toward higher rates of use among girls beginning around age 13 and the prevalence of nicotine-cannabis co-use point to the need for prevention strategies that account for differences in age, sex and patterns of substance use. These findings also provide an important national benchmark for future research. By establishing when substance use emerges and how patterns evolve during adolescence, researchers can better investigate how substance use may intersect with brain development, mental health and other long-term outcomes. MedicalResearch.com: What recommendations do you have for future research as a result of this study? Dr. Sullivan: It will be important to investigate why substance use patterns diverge between boys and girls around age 13 and to identify the factors that contribute to higher rates of use among girls during later adolescence. Additional research should examine the factors associated with polysubstance use, particularly nicotine and cannabis co-use, and determine whether using multiple substances is associated with different developmental or health outcomes than using a single substance. Future studies could also explore how family environment, peer relationships, mental health, social conditions and changing perceptions of substance-related risks influence when and how adolescents begin using substances. MedicalResearch.com: Is there anything else you would like to add? Any disclosures? Dr. Sullivan: One important point is that these findings should not be interpreted to mean that most adolescents use substances. The study found that substance use increases with age, but the majority of young people in the cohort had not reported using substances by age 16. The value of this research is in identifying when use becomes more common and the specific patterns that emerge, so that prevention efforts can be targeted at the times and populations when they may have the greatest impact. Disclosures: The study was funded by the National Institute on Drug Abuse (NIDA) through National Institutes of Health awards DA064409, DA062011, DA050779, DA054980 and DA062432. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

27 Jul UCSD Study: Girls Overtake Boys in Adolescent Substance Use After Age 13, With Nicotine-Cannabis Co-Use Most Common

Posted at 22:01h in Addiction, Cannabis, Pediatrics, Tobacco Research

MedicalResearch.com Interview with:

Ryan M. Sullivan, PhD

Postdoctoral Research Fellow, UC San Diego School of Medicine

[caption id="attachment_75281" align="alignleft" width="200"]

<div style="background:#fff4e5;border-left:4px solid #e07b00;border-radius:4px;padding:16px 20px;margin-bottom:1.5em;font-size:0.95em;color:#5a3e00;line-height:1.7;font-family:Georgia,serif;"><p style="margin:0;"><strong>Cannabis and CBD Product Notice:</strong> Cannabis and CBD products are not FDA-monitored or approved for the treatment of anxiety, depression, or any other mental health condition and are not legal in all locations. Effects vary significantly between individuals. Do not use if you are pregnant, nursing, or may become pregnant. Keep out of reach of children. Children and pets should not be exposed to these products. Cannabis and CBD products may interact with alcohol and other drugs including prescription medications. Always consult your physician or qualified healthcare provider before using any cannabinoid product, especially if you have an existing health condition or take other medications.</p> </div> <div style="background:#f0f4f8;border:1px solid #ccc;border-radius:4px;padding:20px 24px;margin-bottom:2em;font-family:Georgia,serif;color:#1a1a2e;"> <p style="margin:0 0 6px 0;"><strong>MedicalResearch.com Interview with:</strong></p> <p style="margin:0 0 4px 0;"><strong>Ryan M. Sullivan, PhD</strong></p> <p style="margin:0;">Postdoctoral Research Fellow, UC San Diego School of Medicine</p> </div> [IMAGE GOES HERE] <!--more--> <p style="font-family:Georgia,serif;font-size:16px;line-height:1.7;color:#444;font-style:italic;margin-bottom:1.5em;">Study: Sullivan RM, Wallace AL, Shankula CA, et al. Substance use patterns from late childhood to mid-adolescence: Updates on the Adolescent Brain Cognitive Development Study. <em>Drug and Alcohol Dependence Reports.</em> 2026;20:100463. <a href="https://doi.org/10.1016/j.dadr.2026.100463" target="_blank" rel="noopener noreferrer" style="color:#1a7abf;">https://doi.org/10.1016/j.dadr.2026.100463</a></p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>MedicalResearch.com: What is the background for this study?</em></strong></p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>Dr. Sullivan:</em></strong> Adolescence is a critical period for brain development and a time when many young people begin experimenting with alcohol, cannabis, nicotine and other substances. Understanding when substance use begins, how it changes as young people get older, and which substances are most commonly used together can help researchers identify opportunities for prevention and better understand how early substance use may relate to later health outcomes. This study used data from the <a href="https://nida.nih.gov/research-topics/adolescent-brain-substance-use" target="_blank" rel="noopener noreferrer" style="color:#1a7abf;">Adolescent Brain Cognitive Development (ABCD) Study</a>, one of the largest longitudinal studies of youth in the United States, to provide an updated picture of substance use patterns from late childhood through mid-adolescence. Related MedicalResearch.com research has also found that <a href="https://medicalresearch.com/cognitive-brain-circuits-altered-in-youth-with-significant-cannabis-use/" target="_blank" rel="noopener noreferrer" style="color:#1a7abf;">cognitive brain circuits are altered in youth with significant cannabis use</a> — underlining why tracking when and how adolescents begin using substances matters for understanding long-term neurodevelopmental outcomes.</p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>MedicalResearch.com: What are the main findings?</em></strong></p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>Dr. Sullivan:</em></strong> The study found that substance use increased steadily as participants moved through adolescence. By age 16, 38% of participants reported having used at least one substance during their lifetime. Alcohol, cannabis and nicotine were the substances most commonly reported.</p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;">The researchers also identified differences by sex. Boys reported higher rates of substance use before age 12, but beginning around age 13, girls reported higher rates of alcohol, cannabis and nicotine use, with the largest differences seen for nicotine. Polysubstance use — using two or more substances — was also relatively common, with nearly 15% of participants reporting it during the study. The most common combination was nicotine and cannabis, and girls reported higher rates of polysubstance use after age 13, particularly combinations involving nicotine.</p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;">Importantly, estimates adjusted to better reflect the U.S. population were very similar to the study's unadjusted estimates, suggesting that the ABCD cohort provides a useful representation of national patterns of adolescent substance use.</p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>MedicalResearch.com: What should readers take away from your report?</em></strong></p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>Dr. Sullivan:</em></strong> The key takeaway is that substance use becomes increasingly common as young people move through adolescence, highlighting the importance of prevention and early intervention before or during the early teen years. The findings also show that substance use does not follow the same pattern for everyone. In particular, the shift toward higher rates of use among girls beginning around age 13 and the prevalence of nicotine-cannabis co-use point to the need for prevention strategies that account for differences in age, sex and patterns of substance use.</p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;">These findings also provide an important national benchmark for future research. By establishing when substance use emerges and how patterns evolve during adolescence, researchers can better investigate how substance use may intersect with brain development, mental health and other long-term outcomes.</p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>MedicalResearch.com: What recommendations do you have for future research as a result of this study?</em></strong></p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>Dr. Sullivan:</em></strong> It will be important to investigate why substance use patterns diverge between boys and girls around age 13 and to identify the factors that contribute to higher rates of use among girls during later adolescence. Additional research should examine the factors associated with polysubstance use, particularly nicotine and cannabis co-use, and determine whether using multiple substances is associated with different developmental or health outcomes than using a single substance. Future studies could also explore how family environment, peer relationships, mental health, social conditions and changing perceptions of substance-related risks influence when and how adolescents begin using substances.</p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>MedicalResearch.com: Is there anything else you would like to add? Any disclosures?</em></strong></p> <p style="font-family:Georgia,serif;font-size:18px;line-height:1.8;color:#1a1a2e;"><strong><em>Dr. Sullivan:</em></strong> One important point is that these findings should not be interpreted to mean that most adolescents use substances. The study found that substance use increases with age, but the majority of young people in the cohort had not reported using substances by age 16. The value of this research is in identifying when use becomes more common and the specific patterns that emerge, so that prevention efforts can be targeted at the times and populations when they may have the greatest impact.</p> <p style="font-family:Georgia,serif;font-size:16px;line-height:1.8;color:#1a1a2e;"><strong>Disclosures:</strong> The study was funded by the National Institute on Drug Abuse (NIDA) through National Institutes of Health awards DA064409, DA062011, DA050779, DA054980 and DA062432. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.</p> <p style="font-size: 13px; color: #666; background: #f0f0f0; border: 1px solid #d8d8d8; padding: 14px 18px; margin-top:2em;"><strong>Disclaimer:</strong> The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.</p>

Dr. Ryan Sullivan PhD[/caption]

MedicalResearch.com: What is the background for this study?

Dr. Sullivan: Adolescence is a critical period for brain development and a time when many young people begin experimenting with alcohol, cannabis, nicotine and other substances. Understanding when substance use begins, how it changes as young people get older, and which substances are most commonly used together can help researchers identify opportunities for prevention and better understand how early substance use may relate to later health outcomes. This study used data from the Adolescent Brain Cognitive Development (ABCD) Study, one of the largest longitudinal studies of youth in the United States, to provide an updated picture of substance use patterns from late childhood through mid-adolescence. Related MedicalResearch.com research has also found that cognitive brain circuits are altered in youth with significant cannabis use — underlining why tracking when and how adolescents begin using substances matters for understanding long-term neurodevelopmental outcomes.

09 Jul How Proper CBD Oil Administration Supports Sleep and Ease in Neurological Wellness

Posted at 11:38h in Cannabis

Cannabis/CBD Notice: Cannabis products are not FDA monitored or approved. Discuss your use of medicinal cannabis or CBD products with your healthcare provider before use. Dosing is variable and products may interfere with other medications, stimulants and alcohol. Do not use cannabis or CBD products if you are pregnant, nursing, or may become pregnant. Do not use cannabis products when driving or operating difficult or dangerous machinery. Keep out of reach of children. Children and pets should not be exposed to cannabis or CBD products. See below for full disclaimer.

Living with a neurological condition brings daily challenges that go beyond physical symptoms like tremors or muscle stiffness. Many people also struggle with persistent fatigue, poor sleep, and chronic discomfort. While standard medical treatments focus on movement and motor function, addressing sleep quality and mental calm is equally important for maintaining quality of life.

Plant-based approaches are gaining increasing attention in healthcare discussions. Cannabidiol (CBD) offers a way to support calmness and relaxation without intoxicating effects. For those interested in exploring this option, regulated medical platforms such as Releaf provide expert guidance, personalised dosing advice, and third-party tested products.

[caption id="attachment_74881" align="aligncenter" width="500"]

Photo by Kindel Media[/caption]

08 Jul The Evolving Clinical Efficacy of Cannabidiol for Chronic Pain and Patient Access in Australia

Posted at 10:35h in Cannabis, Pain Research

Cannabis/CBD Notice: Cannabis products are not FDA monitored or approved. Discuss your use of medicinal cannabis or CBD products with your healthcare provider before use. Dosing is variable and products may interfere with other medications, stimulants and alcohol. Do not use cannabis or CBD products if you are pregnant, nursing, or may become pregnant. Do not use cannabis products when driving or operating difficult or dangerous machinery. Keep out of reach of children. Children and pets should not be exposed to cannabis or CBD products.

Chronic pain continues to be a complex challenge in modern medicine, driving significant research into non-opioid alternatives. Among the most closely monitored developments is the clinical application of cannabidiol (CBD). In Australia, the intersection of evolving clinical efficacy data and highly regulated patient access frameworks presents a fascinating case study in modern pain management.

For broader context on why medicinal cannabis is attracting clinical attention globally, see this overview of five reasons it is used for pain management, as well as this deeper look at how cannabinoids interact with the endocannabinoid system.

[caption id="attachment_74821" align="aligncenter" width="500"]

Photo by Kindel Media[/caption]

29 Jun 5 Things Patients Should Know Before Trying CBD Gummies for Sleep

Posted at 11:35h in Cannabis, Sleep Disorders

Cannabis / CBD Notice: CBD and cannabidiol-based products are not approved by the U.S. Food and Drug Administration to diagnose, treat, cure, or prevent any disease or medical condition, including sleep disorders. The legal status of CBD products varies by state and country. These products may interact with prescription medications. Always consult a qualified healthcare provider before using any CBD or cannabis-derived product, particularly if you are pregnant, nursing, taking medications, or have an underlying health condition. MedicalResearch.com and Eminent Domains Inc. do not warrant or endorse any CBD product, brand, or supplier referenced in this post. Cannabis products should not be used if you are pregnant, nursing or may become pregnant or while driving or performing potentially dangerous tasks. Keep out of reach of children and pets.

The appeal of CBD gummies for sleep is easy to understand. Something natural, no prescription required, no morning grogginess or addiction risk associated with conventional sleep aids. But the gap between what CBD gummies can realistically do and what the marketing often implies is wider than most first-time buyers realize. Getting clear on the science, the product standards, and the practical approach before you start will save you the frustration of buying something that does not match your situation.

1. CBD Works on Sleep Differently Than You Might Expect

CBD does not make you sleepy the way antihistamines or sedatives do. It does not switch off your brain. What research suggests it may do is reduce the anxiety and physiological arousal that prevents sleep from coming. A review published in PubMed by the National Library of Medicine found that CBD demonstrated anxiolytic effects in clinical research, with participants reporting reduced anxiety without impaired alertness. Since anxiety and an overactive stress response are among the most common drivers of poor sleep onset, the mechanism makes clinical sense even if the evidence base is still developing. What this means practically: CBD gummies for sleep tend to work best for people whose sleep problem involves difficulty switching off mentally rather than a primary sleep disorder. If you lie awake with a racing mind, CBD is more likely to help than if you fall asleep easily but wake repeatedly at 3am. [caption id="attachment_74582" align="aligncenter" width="500"]

Pexels image[/caption]

Understanding-Cannabis-Types-and-Their-Differences

21 Jun Understanding Cannabis Types: Indica, Sativa, and Hybrid Explained

Posted at 21:40h in Cannabis

Cannabis Notice: Cannabis laws and regulations vary by country, state, and territory. Cannabis use is intended for adults only and is illegal in many jurisdictions. This article is for educational purposes only and does not constitute medical advice. Cannabis products discussed here are not endorsed by MedicalResearch.com or Eminent Domains Inc. The effects of cannabis vary by individual, and some people may experience adverse reactions. Always consult a qualified healthcare provider before using cannabis, particularly if you have a medical condition, are pregnant or breastfeeding, or are taking prescription medications. Do not use cannabis and drive or operate heavy machinery. Keep cannabis products out of reach of children and pets.

Cannabis is a plant that has gained a lot of attention in recent years. You might have heard friends or adults talk about it, but do you really understand what it is? Cannabis comes in many different types, each with its own unique effects and uses. Learning about these cannabis types can help you understand why people use them and how they can affect our bodies and minds.

What Is Cannabis?

Cannabis is a flowering plant that has been used for thousands of years. It contains special compounds called cannabinoids, which can affect the human body in various ways. Two of the most well-known cannabinoids are THC (tetrahydrocannabinol) and CBD (cannabidiol). THC is the compound that produces the feeling of being "high," while CBD is known for its calming effects without producing intoxication.

If you're interested in learning more about cannabis and possibly trying it out, you can visit https://gooddayfarmdispensary.com/dispensaries/ for information about local dispensaries and the various options they offer. Knowledge is key to making informed choices for your personal experience.

12 Jun Cannabis and Cancer: Science, Symptoms, and Survival: See the Youtube Documentary

Posted at 21:16h in Author Interviews, Cancer Research, Cannabis

Editor's Note: Cannabis laws and regulations vary by country, state, and territory. This interview is for educational purposes only. Cannabis products discussed here are not endorsed by MedicalResearch.com. Patients should consult their oncologist or healthcare provider before using any cannabis or cannabinoid product, particularly during cancer treatment. Cannabis products should not be used while driving, by children, if pregnant, nursing or planning to become pregnant or mixed with other substances that can affect cognition. Cannabis products may also be contraindicated in other medical conditions or situations.

MedicalResearch.com Interview with: Raphael E. Cuomo, PhD Associate Professor University of California, San Diego Developer and Host, Cannabis and Cancer (Apple TV Documentary)

MedicalResearch.com: What is the background for this documentary? What are the primary components of cannabis plants? Response: I created Cannabis and Cancer because cannabis is now widely discussed by patients, clinicians, policymakers, and the general public, but there is still a lot of confusion about what the science actually says. Much of the public conversation treats cannabis as either broadly harmful or broadly beneficial. The reality is more complex. The documentary is meant to separate questions that are often conflated: whether cannabis exposure may influence the risk of developing cancer, whether cannabis use may affect cancer treatment or symptoms, and whether it may influence survival after a cancer diagnosis. These are very different scientific questions, and each one requires a different type of evidence. Cannabis plants contain many biologically active compounds. The most widely discussed are cannabinoids, especially THC and CBD. THC is the main intoxicating compound and is responsible for many of the psychoactive effects. CBD is not intoxicating in the same way, but it still has biological effects. Cannabis also contains other cannabinoids, terpenes, flavonoids, and plant compounds that may influence how different products affect the body.

12 May Adolescents View Cannabis as Less Harmful Than Alcohol and Tobacco — New California Survey Data

Posted at 00:21h in Cannabis, Pediatrics

Editor's note: This piece discusses mental health issues. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255.

Please note: Cannabis laws and regulations vary by state and locality. Cannabis use may have significant health risks, particularly for adolescents, pregnant individuals, and those with a history of mental health conditions. Cannabis has not been approved by the FDA for most uses and may interact with medications. Do not use cannabis as a substitute for medical treatment. The information in this post is for educational purposes only and does not constitute medical or legal advice. Always consult your physician or qualified healthcare provider before making decisions about cannabis use. Do not use cannabis products if pregnant, nursing or may become pregnant. Children should never be exposed to cannabis products.

MedicalResearch.com Interview with: [caption id="attachment_73658" align="alignleft" width="130"]

Prof. Shu-Hong Zhu[/caption] Shu-Hong Zhu, Ph.D. Professor of Family Medicine and Public Health and Director of the Center for Research and Intervention in Tobacco Control (CRITC) University of California, San Diego MedicalResearch.com: What is the background for this study? Response: Cannabis use in the U.S. has steadily increased over recent decades. As use rates increased, perceptions that cannabis use is harmful have trended in the opposite direction. Declining harm perceptions in the broader population are concerning in part because of their influence on adolescents. Regular cannabis use during adolescents can negatively impact overall functioning, cognition, and educational achievement. It can lead to depression, psychosis, and suicidality. If young people don’t perceive cannabis as harmful, they are more likely to use it and suffer these effects. The purpose of this study was to investigate the extent to which adolescents view the everyday and occasional use of cannabis as harmful, and to compare their perceptions of cannabis to their perceptions of alcohol, cigarettes, and nicotine vapes. It used data from over 160,000 students who took the 2019−2020 California Student Tobacco Survey and over 16,000 who took the 2024 California Youth Tobacco Survey.

08 May Here’s How Cannabis May Alleviate Stress and Anxiety

Posted at 11:26h in Cannabis, Stress

From promoting relaxation to improving sleep quality, cannabis is increasingly explored as a natural option for managing stress and anxiety — here are five ways it may help....

08 May Clinical Advancements in Cannabidiol Therapeutics and the Shift Toward Specialised Care Models

Posted at 10:51h in Cannabis

[caption id="attachment_73613" align="aligncenter" width="500"]

Pexels[/caption]

Please note: Cannabis and cannabidiol (CBD) products are generally not FDA tested or approved for all conditions referenced in this article. Cannabis and CBD products can interfere with medications including blood pressure medications and anticoagulants. Do not use cannabis products if pregnant, nursing or planning to become pregnant. Do not delay seeking medical attention for medical concerns by using cannabis or CBD products without medical advice. Cannabis products should not be used while driving or operating machinery. Statements and product contents have not been independently confirmed by MedicalResearch.com or Eminent Domains Inc. Please discuss any and all cannabis or CBD use with your health care provider before beginning any such regimen.

The landscape of chronic condition management has undergone a significant transformation over the past decade. For years, the medical community relied heavily on isolated symptom treatments and traditional pharmacological interventions to manage complex ailments. Patients suffering from long-term conditions like neuropathy, chronic inflammation, or severe anxiety frequently found themselves cycling through various medications with limited success and significant side effects. These recurring challenges have prompted healthcare professionals to rethink standard protocols. The latest clinical evidence supports a multidimensional approach to chronic pain that incorporates alternative and complementary therapies, reflecting a broader shift away from conventional, single-track treatments. As recent insights into pain management demonstrate, invasive procedures and heavy medications are no longer the default first-line defense. Instead, clinicians are increasingly advocating for whole-person care that values patient lifestyle strategies, psychological support, and alternative therapeutics. Among these emerging alternatives, cannabidiol has garnered substantial attention from the global medical and academic communities as a viable option for those who have exhausted standard therapies.

Edward Liu, MD Geisinger College of Health Sciences Scranton, PA 18509

27 Apr Declines and pronounced state-level disparities in tetrahydrocannabinol (THC) prescribing to Medicare patients

Posted at 19:27h in Cannabis

[caption id="attachment_73447" align="alignleft" width="142"]

Dr. Edward Liu[/caption] MedicalResearch.com Interview with: Edward Liu, MD Geisinger College of Health Sciences Scranton, PA 18509 Medicalresearch.com: What is the background for this study? Response: Prescription drugs have high levels of uniformity that plant-based products cannot achieve. Given the liberalization of state-laws regarding medical marijuana¹ over the past three-decades and increasing evidence of evidence of cannabis for conditions like chronic pain,² we were interested in the use of the prescription formulation of delta(Δ)9-tetrahydrocannabinol (THC). A prior pharmacoepidemiology report found that prescription THC (dronabinol) to Medicaid patients decreased from 2016 to 2020. There were also pronounced state-level disparities in prescribing with a 130-fold difference when correcting for population between the highest and lowest states. There was no research on this topic among Medicare patients. To address this gap, we obtained prescription numbers nationally and at a state level from 2014 to 2019 for Medicare Part D patients.

27 Apr The Pharmacokinetics of the Last Mile: Protecting Cannabinoid Integrity in 2026

Posted at 19:19h in Cannabis, Medical Equipment

[caption id="attachment_73444" align="aligncenter" width="500"] Protecting Cannabinoid Integrity

Source: IMAGE[/caption]

Editor's note: Cannabis and THCA/Hemp CBD products should have an active ingredient list on the container and a Certificate of Analysis (COA). Discuss your use of THC, cannabis, or CBD products with your health care provider. Dosing of cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use cannabis products including edibles, drinks, and CBD if you are pregnant, nursing, or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products.

Whereas logistics professionals are more likely to concentrate on the purity and quality of laboratory extractions or cultivations, one of the most unstable parts of the medicinal substance's route to delivery — the final mile — may sometimes be neglected. The cannabis industry has turned to a pharmaceutical approach in 2026 to safeguard the chemical composition of the plant from exposure to damaging effects before reaching the end user.

The Science of Thermal Degradation and Molecular Shifts

The main challenge is the heat issue, which is considered the major cause of irregularity among chemicals. Research results from the beginning of 2026 indicate that different temperatures during transportation can affect the composition of cannabis within three hours by 15%.

27 Apr What Long-Term Cannabis Use Does to Brain Connectivity

Posted at 10:22h in Cannabis

[caption id="attachment_73415" align="aligncenter" width="500"]

Unsplash image[/caption]

Cannabis research has always straddled a gray area. Popular takes are sometimes upended following a "groundbreaking" study. And yet, what we do know about its effects on the brain barely scratches the surface. Coincidentally, scientists are venturing into neurological territory and expanding their focus on brain function and connectivity. Harvard Medical School, for one, is pioneering studies utilizing neuroimaging techniques like functional MRI to determine how cannabis affects the mind.

25 Apr Researchers Found Why CBD Affects Anxiety Differently in Each Person

Posted at 17:31h in Cannabis, Mental Health Research

[caption id="attachment_73388" align="aligncenter" width="500"]

SOURCE: IMAGE[/caption]

A question that comes up constantly in cannabis research is one that patients have been asking for years: why does CBD ease anxiety in one person and make another feel worse? For a long time, the honest answer was that nobody fully knew. A landmark study out of McGill University changedthat, and the findings reveal something that most consumer guides on CBD have never properly explained.

The answer is not about product quality, dosage form, or brand. It comes down to how cannabis interacts with serotonin — and specifically why that interaction is not the same at every dose.

Meagan Robichaud, PhD, MPH Post-Doctoral Associate Center for Rapid Surveillance of Tobacco Rutgers Institute for Nicotine & Tobacco Studies

25 Mar Delta-8 THC Product Packaging Often Incomplete, Confusing or Misleading

Posted at 18:32h in Cannabis

Editor’ note: Cannabis and THCA/HEMP/ CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider. Dosing of Cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles, drinks and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products.l MedicalResearch.com Interview with: [caption id="attachment_72930" align="alignleft" width="200"]

Meagan Robichaud, Ph.D.[/caption] Meagan Robichaud, PhD, MPH Post-Doctoral Associate Center for Rapid Surveillance of Tobacco Rutgers Institute for Nicotine & Tobacco Studies MedicalResearch.com: What is delta-8 THC? Response: To understand delta-8 THC, it’s first important to understand the primary components of cannabis: THC (tetrahydrocannabinol) and CBD (cannabidiol). THC—typically referring to delta-9 THC—is the primary intoxicating substance in cannabis—it’s what makes consumers feel “high.” CBD is also abundant in cannabis but is non-intoxicating. Delta-8 THC is an isomer of delta-9 THC—meaning it has the same chemical formula as delta-9 THC but with a slightly different arrangement of atoms. While early research suggest that delta-8 THC is less potent than delta-9 THC, delta-8 THC is still an intoxicating substance. Delta-8 THC naturally exists in very small amounts in cannabis plants but can be synthesized from CBD.

Carrie Cuttler, Ph.D. The Health & Cognition (THC) Lab Associate Professor Director, Experimental Psychology Doctoral Program Co-Director, Cannabis Research Center (CRC) Department of Psychology Washington State University

12 Mar WSU Study: Avoid Cannabis When Relying on Memory is Important

Posted at 19:12h in Addiction, Author Interviews, Cannabis, Memory

Dr. Cutttler, Ph.D.[/caption] Carrie Cuttler, Ph.D. The Health & Cognition (THC) Lab Associate Professor Director, Experimental Psychology Doctoral Program Co-Director, Cannabis Research Center (CRC) Department of Psychology Washington State University MedicalResearch.com: What is the background for this study? Response: One of the most well-documented effects of acute cannabis intoxication is impairment in memory. However, memory is not a single process. It is a complex system made up of multiple distinct subsystems that rely on different neural mechanisms and support different types of remembering. Most prior research examining the acute effects of cannabis in humans has focused on a relatively narrow set of memory tests—primarily verbal memory tasks, which involve recalling lists of words, and working memory tasks, which require temporarily holding and manipulating information in consciousness. Far fewer studies have examined how cannabis affects other types of memory that are more relevant to everyday life. These include temporal order memory (remembering the order in which events occurred), prospective memory (remembering to perform tasks in the future), source memory (remembering where information came from), false memory (recalling information that was never presented), and episodic content memory (recalling personally experienced events). To address this gap, we conducted a randomized, double-blind, placebo-controlled study examining the acute effects of cannabis across multiple memory domains. In total, 120 participants were randomly assigned to vaporize either a placebo, a moderate dose of cannabis (20 mg THC), or a high dose of cannabis (40 mg THC).

Prof. Joseph (Yossi) Tam, DMD, PhD School of Pharmacy, Institute for Drug Research The Hebrew University of Jerusalem The Harvey M. Krueger Family Center for Nanoscience and Nanotechnology Jerusalem, Israel

06 Mar Hebrew University Study Finds MASLD, a Common Chronic Liver Disorder, May Benefit from Cannabis Derivatives

Posted at 20:47h in Author Interviews, Cannabis, Hepatitis - Liver Disease

Editor’ note: Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider. Dosing of Cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles, drinks and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. MedicalResearch.com Interview with: Prof. Joseph (Yossi) Tam, DMD, PhDSchool of Pharmacy, Institute for Drug Research The Hebrew University of Jerusalem The Harvey M. Krueger Family Center for Nanoscience and Nanotechnology Jerusalem, Israel With colleagues Dr. Liad Hinden, the PhD student Radka Kočvarová, and the Tam’s team at the School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem. MedicalResearch.com: What is the background for this study? Would you describe the condition of Metabolic dysfunction-associated steatotic liver disease (MASLD)? What causes it? Whom does it affect? Response: MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disorder worldwide. It develops when fat accumulates excessively in liver cells, commonly in people with obesity, insulin resistance, high cholesterol, or diabetes. Over time, this condition can progress to inflammation, fibrosis, or cirrhosis. Despite its growing prevalence, effective pharmacological therapies remain limited, leaving a substantial unmet clinical need.

Kelly Young-Wolff, PhD, MPH Licensed clinical psychologist and Research Scientist Kaiser Permanente Northern California Division of Research Associate Professor, Psychiatry School of Medicine UCSF Weill Institute for Neurosciences

22 Feb Kaiser Permanente Study Finds Higher Risk of Psychiatric Disorders in Teens Who Reported Cannabis Use

Posted at 02:05h in Author Interviews, Cannabis, JAMA, Mental Health Research

Dr. Young-Wolff[/caption] Kelly Young-Wolff, PhD, MPH Licensed clinical psychologist and Research Scientist Kaiser Permanente Northern California Division of Research Associate Professor, Psychiatry School of Medicine UCSF Weill Institute for Neurosciences MedicalResearch.com: What is the background for this study? Response: Cannabis is widely used by adolescents, and it’s often first used during the same developmental window when many psychiatric disorders begin to emerge. At the same time, cannabis has become more accessible and more socially accepted. While prior studies have linked adolescent cannabis use to mental health symptoms, fewer large studies have examined whether it’s associated with later clinically diagnosed psychiatric disorders. We wanted to address that gap.

Chu Chen, PhD Professor and Joe R. and Teresa Lozano Long Chair in Neural Physiology Department of Cellular and Integrative Physiology Center for Biomedical Neuroscience Joe R. and Teresa Lozano Long School of Medicine University of Texas at San Antonio Health Science Center San Antonio, TX 78229

06 Feb UT Health San Antonio Study Finds Lows Dose THC Plus Celecoxib May Prevent or Delay Onset of Alzheimer’s Disease

Posted at 14:47h in Alzheimer's - Dementia, Author Interviews, Cannabis

Editor's note: Do Not Use these products alone or in combination without the specific guidance of your health are provider, due to risks of untoward side effects. THC/CBD and other cannabis products should not be used if you are pregnant, planning to become pregnant or nursing. Children should not be exposed to cannabis in any form. MedicalResearch.com Interview with: [caption id="attachment_72277" align="alignleft" width="200"]

Prof. Chu Chen[/caption] Chu Chen, PhD Professor and Joe R. and Teresa Lozano Long Chair in Neural Physiology Department of Cellular and Integrative Physiology Center for Biomedical Neuroscience Joe R. and Teresa Lozano Long School of Medicine University of Texas at San Antonio Health Science Center San Antonio, TX 78229 MedicalResearch.com: What is the background for this study? Response: Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, yet no effective therapies currently exist to prevent, treat, or halt its progression. Cannabis has been used for thousands of years for both recreational and medicinal purposes; however, its therapeutic application has been limited by undesirable neurocognitive side effects, particularly impairments in learning and memory. Δ9-Tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of cannabis, has been shown to reduce amyloid-β (Aβ) pathology in animal models of AD, but at high doses (>5.0 mg/kg) it also disrupts synaptic function and impairs cognition. Research from our laboratory and others has demonstrated that Δ9-THC-induced deficits in long-term synaptic plasticity, learning, and memory are associated with the induction of cyclooxygenase-2 (COX-2), an inducible enzyme that converts arachidonic acid into pro-inflammatory prostaglandins. Notably, pharmacological inhibition or genetic deletion of COX-2 attenuates Δ9-THC-induced synaptic and cognitive impairments. Based on these findings, we proposed a combination (“cocktail”) therapy consisting of low-dose Δ9-THC and the anti-inflammatory drug celecoxib, a selective COX-2 inhibitor, as a potential therapeutic strategy for AD. This approach is designed to preserve the beneficial effects of Δ9-THC while minimizing its adverse neurocognitive effects and COX-2-mediated inflammatory responses.

Saji George PhD Associate Professor & Chair, Department of Food Science and Agricultural Chemistry Canada Research Chair in Sustainable Nanotechnology for Food and Agriculture Faculty of Agricultural and Environmental Sciences, McGill University Quebec, Canada

02 Feb Cannabis Products Not Necessarily Free of Toxigenic Fungi and Pathogens

Posted at 21:14h in Addiction, Author Interviews, Cannabis

MedicalResearch.com Interview with: [caption id="attachment_72231" align="alignleft" width="200"]

Dr. Saji George[/caption] Saji George PhD Associate Professor & Chair, Department of Food Science and Agricultural Chemistry Canada Research Chair in Sustainable Nanotechnology for Food and Agriculture Faculty of Agricultural and Environmental Sciences, McGill University Quebec, Canada MedicalResearch.com: What is the background for this study? Response: Cannabis plants are highly susceptible to microbial contamination, particularly by fungi producing harmful mycotoxins. Infection of plants by fungal pathogens could result in the contamination of cannabis products with mycotoxins that pose serious health risks, especially for immunocompromised patients who use cannabis for medical purposes. Currently industry employ decontamination methods such as gamma irradiation to clean up cannabis products likely to harbor fungi and their metabolites. However, their effectiveness in fully eliminating toxigenic fungi and associated mycotoxins remains unclear. Our studies aimed to evaluate the persistence of fungi and mycotoxins in dried cannabis buds following gamma irradiation, using a combination of culture-based, molecular, and immunological techniques. These studies revealed that complete sterilization of cannabis buds once contaminated with mycotoxin is extremely difficult and highlighted the importance of early interventions in preventing toxigenic fungi during cultivation.

31 Jan A Marijuana Card Without the Awkward Doctor Visit

Posted at 10:23h in Cannabis

Editor’ note: Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider. Dosing of Cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles and drinks and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. Getting a medical marijuana card no longer feels like a tense appointment filled with uncomfortable questions. The old process left many people nervous, unsure of what a doctor might think, and hesitant to ask for cannabis as a legitimate option. The shift to online evaluations cleared away much of that stress. Now patients can handle everything from home, using a phone or a laptop. A calm space makes people feel more open, creating a smoother and clearer conversation with their doctor. The entire experience feels more private and respectful of personal comfort. [caption id="attachment_72196" align="aligncenter" width="500"]

Photo by Nataliya Vaitkevich[/caption]

People Love the Online Approach

Many patients wanted a simpler, more relaxed way to get certified. Traveling to a clinic, sitting in a waiting room, and facing a doctor in person often made the process feel more complicated than it needed to be. Online evaluations solved this by removing nearly every stressful step. This is where Elevate Holistics helped set a new standard, proving that a digital visit could still feel personal and trustworthy. People also enjoy the flexibility of choosing an appointment time that fits their actual lives. For individuals with mobility challenges, limited transportation, or packed schedules, this option opens the door to care that might have felt out of reach. That shift increased access in a real and meaningful way.

26 Jan Univ Michigan Study Finds People Who Use Cannabis Drinks Reduce Alcohol Consumption, Even More that Those Who Use Other Cannabis Products

Posted at 22:42h in Alcohol, Author Interviews, Cannabis

Editors' note: Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider. Dosing of CBD is variable, especially since it is not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. Do not use Cannabis products including edibles, drinks or CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. It is unknown whether the effects of alcohol plus cannabis are cumulative and users ingesting both products should be especially cautious to avoid driving or other activities requiring alertness and judgement. MedicalResearch.com Interview with: [caption id="attachment_72135" align="alignleft" width="100"]

Dr. Kruger .[/caption] Daniel J. Kruger, PhD Population Studies Center, Institute for Social Research University of Michigan [caption id="attachment_72136" align="alignleft" width="100"]

Dr. Kruger[/caption] MedicalResearch.com: What is the background for this study? [caption id="attachment_72137" align="alignleft" width="100"]

Dr. Felicione[/caption] Response: Alcohol consumption, especially heavy alcohol consumption, is associated with many health risks and nearly 200 different health conditions and diseases. Reducing alcohol consumption reduces the risks and harms from alcohol. Previous research has demonstrated that people have reduced their alcohol consumption when they have access to cannabis. Cannabis beverages have emerged in States where cannabis is legal for adult or medical use.

23 Dec Navigating Chronic Relief: The Role of Regulated Alternative Therapies in Modern Healthcare

Posted at 13:04h in Cannabis, Pain Research

Discover the safety benefits of state-regulated integrative medicine. Learn why obtaining a Medical Marijuana Card ensures legal protection and doctor-supervised care....

26 Nov Exploring the Boom of Subtle, Modern-Day Wellness Helpers

Posted at 12:01h in Cannabis

Editor’ note: Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA)/Discuss your use of THC, Cannabis or CBD products with your health care provider. Dosing of CBD is variable, especially since it is not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products.

Wellness today looks very different from what it was even five years ago. People now want relief that is quiet, simple, and easy to integrate into a busy lifestyle. This shift has led to the rise of subtle, modern-day wellness tools and products designed to support balance without demanding time or major daily changes. Innovations such as CBD patches wholesale, clean CBD liquid wholesale solutions, and fast-acting CBD shots in the UK demonstrate just how far the wellness landscape has evolved. For many consumers, the new goal isn’t dramatic transformation; it’s small, consistent improvements that feel effortless. The modern consumer is more informed, more selective, and more focused on practicality than ever before. Instead of relying on complicated wellness rituals or lengthy sessions of self-care, people now seek micro-relief solutions that deliver genuine benefits in minutes, not hours. This is where subtle aids like patches, liquids, shots, and micro-dose formats have changed the game.

Why Subtle Wellness Is So Popular Today

People don’t want to overhaul their routines they want products that slip into daily life without friction. Subtle wellness solutions work because they remove barriers: no prep time, no steep learning curve, no noticeable interruption. Whether someone is at work, travelling, or winding down at home, these aids offer an easy way to regain balance. Today’s wellness movement is built on three traits:

Convenience

Consumers want tools that don’t demand major adjustments. Subtle wellness allows support anytime, anywhere.

Discretion

Not everyone wants their wellness routines on display. Patches, liquids, and shots offer quiet ways to feel better without drawing attention.

Speed

Stress, tension, and burnout don’t wait for scheduled rituals. People need fast-acting relief they can count on instantly. This is exactly why CBD-focused products have grown so quickly; they fit all three criteria.

25 Nov JAMA: University of Illinois Study Highlights Recents Trends in Cannabinoid Hyperemesis Syndrome

Posted at 15:29h in Author Interviews, Cannabis, JAMA

Dr. Swartz[/caption] MedicalResearch.com Interview with: James A. Swartz, PhD Professor, Jane Addams College of Social Work University of Illinois Chicago MedicalResearch.com: What is the background for this study? Response: For the past 5 1/2 years, my project team has been charged with monitoring the public health effects of adult cannabis use legalization in Illinois. To fulfill that obligation, we have monitored state data and have tried to keep informed about ongoing research on cannabis legalization and public health. Cannabinoid hyperemesis syndrome (CHS) rose to the surface of this continual monitoring through a growing number of publications indicating the prevalence of this condition was on the rise and clinical case reports. As context, for any readers unfamiliar with the clinical syndrome, CHS is a paradoxical reaction to long-term, heavy cannabis use. Instead of relieving nausea, cannabis in some people appears to trigger cycles of severe nausea, vomiting, and abdominal pain. Patients often present repeatedly to emergency departments, undergo extensive workups, and only much later does someone connect the dots and consider CHS. Resource use is substantial. CHS visits often involve repeat ED presentations, imaging, laboratory testing, and sometimes hospital admission. Even though CHS is rarely life-threatening, it is not a trivial condition from either the patient’s or the system’s perspective.

Most of the existing literature has been case reports, small series, or single-center studies. Those reports clearly show that CHS can be debilitating and is frequently misdiagnosed, but they don’t tell us much about the bigger picture:

How often Cannabinoid hyperemesis syndrome is showing up in emergency departments nationally
How those rates have changed over time, especially as cannabis policies and patterns of use have shifted
What the typical patient profile looks like at a population level

Our goal was to step back and use a large national emergency department database to describe CHS at scale in the United States from 2016 through 2022.

MedicalResearch.com Interview with: Victoria Bethel, MSN Department of Public Administration and Policy University of Georgia, Athens

13 Nov Cancer Patients May Be able to Manage Pain with Cannabis Instead of Opioids

Posted at 02:31h in Author Interviews, Cannabis, JAMA, Opiods

[caption id="attachment_71419" align="alignleft" width="150"]

Victoria Bethel[/caption] MedicalResearch.com Interview with: Victoria Bethel, MSN Department of Public Administration and Policy University of Georgia, Athens MedicalResearch.com: What is the background for this study? Response: From the same pool of commercially insured patients, we found that cannabis dispensary openings were associated with reduced opioid prescribing among patients with non-cancer pain. For this study, we examined whether cannabis dispensary openings were also associated with reduced opioid prescribing among commercially insured patients who do have a cancer diagnosis. Similar to patients without cancer, we estimated reductions in opioid prescribing after medical and recreational cannabis dispensaries open. These findings may suggest that patients who experience cancer pain are able to manage their pain with cannabis instead of requiring opioids, although we cannot directly observe substitution.

21 Oct TXCannabis.com guide to medical conditions in Texas

Posted at 09:48h in Cannabis

If you or your loved one is living with a neurological condition, seizure disorder, neurodegenerative illness, spasticity, autism spectrum disorder, cancer or treatment-related symptoms, post-traumatic stress symptoms, or other challenges related to a qualifying diagnosis, the next step is a professional evaluation with a Texas-licensed physician. That evaluation provides certainty....

01 Oct Safe Cannabis Shopping Checklist: What Every Consumer Should Verify Before Buying

Posted at 13:02h in Cannabis

Photo by Kindel Media[/caption] With so many options available online and through local delivery services, it’s important to shop smart. Not every provider follows the same safety and quality standards — which means consumers must know what to look for before placing an order. Licensed and transparent providers make this easy, while unverified sources often cut corners that can put buyers at risk. Here’s a simple checklist to keep in mind before making your next purchase.

✅ Verify Licensing and Compliance

The first step in safe shopping is making sure the business is licensed and compliant with state regulations. Licensed shops are required to meet strict testing, labeling, and storage standards, ensuring safer products for customers.

Confirm that the business is legally operating in your area.
Check for customer reviews that mention professionalism and trustworthiness.
Avoid sellers that don’t clearly disclose compliance details.

Licensed services like Kravings Delivery in Lynwood are trusted by local customers because they prioritize compliance and accountability with every order.

Ibrahim Kamel, MD, MHA Boston Medical Center – Brighton Clinical Instructor Boston Medical Center Boston University

16 Sep EASD 25: Boston University Study Finds Cannabis Use Carries Risk of Type 2 Diabetes

Posted at 00:08h in Author Interviews, Cannabis, Diabetes

[caption id="attachment_70686" align="alignleft" width="150"]

Dr. Kamel[/caption] MedicalResearch.com Interview with: Ibrahim Kamel, MD, MHA Boston Medical Center – Brighton Clinical Instructor Boston Medical Center Boston University MedicalResearch.com: What is the background for this study? Response: Cannabis use carries risk for developing Type 2 diabetes. It is important for physicians to screen for the use of cannabis to better understand each patients risk. MedicalResearch.com: What are the main findings? Response: Clinically physicians should screen for and council on the risk of cannabis use. People should know what is the risk in the substances they use and make the choice that they feel is right.